Medical Cannabis Studies

• View All (505)

Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions (2014)

In this study, the bibliographical review available related to the clinical deficiency of endocannabinoids (CECD) was carried out. Research results have confirmed that the underlying endocannabinoid deficiencies play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions. View study
Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions (2004)

The present study demonstrates that migraine, fibromyalgia, and other related conditions have common clinical, biochemical, and pathophysiologic patterns that could be treated with cannabinoid medications. View study
Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes (2016)

In this research a reconsideration of the clinical endocannabinoid deficiency is made. Current research supports the theory of migraine, fibromyalgia, irritable bowel and other treatment-resistant syndromes View study
Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions (2015)

Cannabinoid receptors may be involved in malignant thyroid transformation. These receptors, especially the CB2 receptor, are potential targets in the therapy of thyroid neoplasia. View study
Consequences of Cannabinoid and Monoaminergic System Disruption in a Mouse Model of Autism Spectrum Disorders (2011)

These experiments demonstrated the therapeutic potential of cannabinoids to help treat autism. View study
Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd edition (2016)

With this update of the consolidated guidelines on the use of antiretroviral drugs to treat and prevent HIV infection, WHO, for the first time, recommends that all people living with HIV receive antiretroviral therapy (ART). In this update We want to provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral drugs (ARV) to treat and prevent HIV infection and the care of people living with HIV. View study
Constantino1997_PosTHC_HempSeed - Hemp Oil Ingestion Causes Positive Urine Tests for Ag-Tetrahydrocannabinol Carboxylic Acid (1997)

Through the urine samples taken from 7 volunteers who consumed 15 milliliters of hemp oil, it was concluded that all the publication samples showed the presence of tetrahydrocannabinol carboxylic acid (THCA) by GC-MS. View study
Consumption and Quantitation of D9-Tetrahydrocannabinol in Commercially Available Hemp Seed Oil Products (2000)

This research aims to quantify the levels of Ag-tetrahydrocannabinol THC in hemp oils available in the market and administer the analyzed oils to volunteers without THC to determine the levels of metabolites in the urine after several doses of 15 g. View study
Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression- implications for schizophrenia (2012)

It was concluded in this study that the findings that reduce the expression of glutamic acid ribonucleic acid (mRNA) (GAD67), can induce a lower expression of cannabinoid receptor 1 mRNA (CB1R), support the hypothesis that cortical levels Lower CB1R levels in schizophrenia can partially compensate for the deficiency of GABA-mediated gamma amino butyric acid (GABA) synthesis by reducing the suppression of endogenous cannabinoids from GABA release. View study
Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. (2019)

Drug-resistant epilepsy has a negative impact on quality of life and is associated with increased morbidity and mortality and high costs for the health system. The purpose of this systematic review was to look for cost-effectiveness analyzes that include the treatment of pediatric drug-resistant epilepsy with cannabis-based products to inform public health payers about making decisions about the reimbursement of these products. View study
COX-2 and PPAR-g Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells (2012)

These data reveal a new proapoptotic mechanism of cannabidiol that involves the initial positive regulation of cyclooxygenase-2 COX-2 and PPAR-g and a subsequent nuclear translocation of PPAR-g by PG-dependent COX-2. View study
Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries (2014)

In this research, we intend to study the vasorelaxant effect of 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. Through the results, it was demonstrated for the first time that 2-AG causes vasorelaxation of the human mesenteric arteries View study